GenVec president and ceo to retire

US firm hires recruitment firm to find a successor

GenVec, a US biopharmaceutical company that uses differentiated, proprietary technologies to create therapeutics and vaccines, says Paul Fischer plans to retire as president and chief executive. Dr Fischer will continue in the role until a successor is named and the ceo transition is complete. The Board will use Spencer Stuart, an executive search firm, to advise it on potential candidates.

Fischer has been with the Gathersburg, MD firm for 15 years.

You may also like

Manufacturing

Continuous innovation: redefining the future of pharmaceutical manufacturing

In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
Pharmaceutical

Keystone Folding Box Co. unveils Key-Pak Plus

Designed to protect children and empower seniors, it achieves top U.S. safety ratings and meets global accessibility standards
Pharmaceutical

Bavarian Nordic launches chikungunya vaccine Vimkunya in the UK

The UK announcement of the recombinant vaccine follows recent approval by the MHRA in May 2025
Research & Development

Servier and IDEAYA Biosciences join forces to bring a promising new eye cancer treatment to patients across the globe

Servier and IDEAYA Biosciences have entered into an exclusive license agreement for regulatory and commercial rights to darovasertib outside the US
Pharmaceutical

Atelerix and Rodon Global enter new partnership to create cryo-free logistics

The initial agreement will be to incorporate Atelerix’s non-cryogenic cell preservation technology into Rodon's international freight and logistics services for drug discovery and clinical trials
Pharmaceutical

Piramal Pharma Solutions supports George Medicines in developing its new drug for hypertension

Piramal Pharma Solutions extended its robust CDMO capabilities to George Medicines to develop WIDAPLIK
Pharmaceutical

Polpharma Biologics signs licensing agreement with MS Pharma for proposed biosimilar candidates

The new agreement has potential to expand regional access to therapies for ulcerative colitis, Crohn's disease, multiple sclerosis and psoriasis patients in the Middle East and North Africa
Subscribe now